Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 4

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e7008-128479

+ Details

Name:	us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of liability recognized arising from contingent consideration in a business combination.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 35

-Paragraph 1

-Subparagraph b

-URI http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 25

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476

+ Details

Name:	us-gaap_BusinessCombinationContingentConsiderationLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Details

Name:	us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Fair value portion of other assets.

+ References

No definition available.

+ Details

Name:	us-gaap_OtherAssetsFairValueDisclosure
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Fair value portion of other liabilities.

+ References

No definition available.

+ Details

Name:	us-gaap_OtherLiabilitiesFairValueDisclosure
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The amount of cash paid for royalties during the current period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (g)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name:	us-gaap_PaymentsForRoyalties
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

Fair Value Measurement - Additional Information (Detail)		3 Months Ended	6 Months Ended	3 Months Ended	6 Months Ended
	Jun. 30, 2014 USD ($)	Jun. 30, 2014 Novozymes Biopharma DK A/S Sweden Ab Milestone Payments EUR (€)	Jun. 30, 2014 Novozymes Biopharma DK A/S Sweden Ab Milestone Payments EUR (€)	Jun. 30, 2014 Bio Flash Minimum USD ($)	Jun. 30, 2014 Bio Flash Minimum USD ($)	Jun. 30, 2014 Refine Technology, LLC USD ($)	Jun. 02, 2014 Refine Technology, LLC USD ($)	Jun. 02, 2014 Refine Technology, LLC Milestone Payments USD ($)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value of other assets	$ 0
Fair value of other liabilities	0
Business acquisition, contingent payment		750,000	750,000
Royalty payment				80,000	80,000
Additional contingent consideration accrued						$ 1,400,000	$ 1,400,000	$ 1,400,000